Quick Answer
Nuvectis Pharma, Inc. reported Operating Income of -$27.57 million for fiscal year 2025.
Nuvectis Pharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$27.57M | -38.9% |
| 2024 | -$19.85M | +13.3% |
| 2023 | -$22.90M | -19.0% |
| 2022 | -$19.23M | -49.2% |
| 2021 | -$12.89M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.79M | -78.8% | -18.2% |
| June 30, 2025 | -$6.59M | -42.0% | -18.4% |
| March 31, 2025 | -$5.57M | -26.7% | -27.7% |
| September 30, 2024 | -$4.36M | +29.2% | +6.1% |
| June 30, 2024 | -$4.64M | +19.6% | -5.6% |
| March 31, 2024 | -$4.40M | -7.2% | +28.6% |
| September 30, 2023 | -$6.16M | -3.7% | -6.7% |
| June 30, 2023 | -$5.77M | -61.5% | -40.7% |
- Nuvectis Pharma, Inc. showed a decrease of -38.9% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Nuvectis Pharma, Inc.’s operating income has declined by 113.9% (from -$12.89 million to -$27.57 million).
- The most recent figure is from Nuvectis Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: